The risk is severe: if the courts find for the innovator, the generic manufacturer faces liability for the innovators lost profits, which for a blockbuster drug can reach into the billions of dollars
Clinical studies, including the SUSTAIN trials, show average weight loss of around 5 kg, although individual results vary
Obesity disrupts bone metabolism and leads to increased bone resorption, but GLP-1RAs can inhibit this damage and improve bone health by increasing the OPG/RANKL ratio, reducing osteoclast activity, and promoting bone formation GLP-1RAs and muscle GLP-1RAs and Muscle Atrophy In previous experiments, exendin-4 (Ex-4) inhibited the expression of myostatin (MSTN), atrophy-factor F-box only protein 32 (atrogin-1) and muscle ring finger protein 1 (MuRF-1) in dexamethasone-treated C2C12 myotubes.376,377,378 In a dexamethasone-induced muscle atrophy model, Ex-4 ameliorated muscle atrophy by inhibiting muscle atrophy factor and enhancing myogenic factors (MyoG and MyoD), thereby increasing muscle mass and function
Patients with diabetes should discuss their condition during the intake questionnaire and initial consultation to determine eligibility
Worth being clear about what it is